Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| ECOG-E4A03T2 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at blood samples from patients with multiple myeloma who were treated with thalidomide or lenalidomide.
OBJECTIVES:
Primary
OUTLINE: Blood samples obtained before, during, and after treatment with thalidomide or lenalidomide from patients previously enrolled on clinical trial ECOG-E4A03 or E-E1A00 are analyzed to determine the total content of cathepsin G (CG) via ELISA; to determine mRNA levels of CG via RT-PCR; and for platelet aggregation studies. Blood samples are collected from healthy volunteers for platelet preparation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| gene expression analysis | Genetic | |||
| reverse transcriptase-polymerase chain reaction | Genetic | |||
| immunoenzyme technique | Other | |||
| laboratory biomarker analysis | Other | |||
| platelet aggregation test | Other |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients with failed disease based on expectations for changes in cathepsin G (CG) levels | 1 month |
| Measure | Description | Time Frame |
|---|---|---|
| Mechanism of development of thalidomide/lenalidomide-induced venous thromboembolism (VTE) | 1 month | |
| Intensity, dynamics, and specificity of CG upregulation in response to thalidomide and lenalidomide treatment | 1 month |
Not provided
DISEASE CHARACTERISTICS:
Meets 1 of the following criteria:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Not provided
Not provided
Not provided
Samples submitted for research from patients enrolled on E4A03 or E1A00
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Suzanne Lentzsch, MD, PhD | University of Pittsburgh | Study Chair |
Not provided
Not provided
Not provided
Not provided
Not provided
| Specificity and threshold levels of CG for induction of platelet aggregation in response to thalidomide and lenalidomide and the resulting risk for VTE development | 1 month |
| ID | Term |
|---|---|
| D009101 | Multiple Myeloma |
| D054219 | Neoplasms, Plasma Cell |
| ID | Term |
|---|---|
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D020141 | Hemostatic Disorders |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D010265 | Paraproteinemias |
| D001796 | Blood Protein Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006474 | Hemorrhagic Disorders |
| D008232 | Lymphoproliferative Disorders |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D020869 | Gene Expression Profiling |
| D020133 | Reverse Transcriptase Polymerase Chain Reaction |
| D007124 | Immunoenzyme Techniques |
| D010974 | Platelet Aggregation |
| ID | Term |
|---|---|
| D005821 | Genetic Techniques |
| D008919 | Investigative Techniques |
| D016133 | Polymerase Chain Reaction |
| D021141 | Nucleic Acid Amplification Techniques |
| D007118 | Immunoassay |
| D007158 | Immunologic Techniques |
| D007150 | Immunohistochemistry |
| D015336 | Molecular Probe Techniques |
| D018056 | Hemorheology |
| D001790 | Blood Physiological Phenomena |
| D002943 | Circulatory and Respiratory Physiological Phenomena |
| D015539 | Platelet Activation |
| D006487 | Hemostasis |
Not provided
Not provided